Cancer is the second-leading cause of death in the United States, according to a 2026 Cancer Research Institute report. Cancer biologists are keenly aware of this statistic, as it drives innovations that revolutionize cancer ...
4 hours ago
0
0
Researchers at The University of Texas MD Anderson Cancer Center have characterized the complex microenvironment in angioimmunoblastic T cell lymphoma (AITL), a type of nodal T cell lymphoma, and identified overexpression ...
Dec 9, 2025
0
9
Over the past 20 years, a class of cancer drugs called CD40 agonist antibodies have shown great promise—and induced great disappointment.
Aug 14, 2025
0
74
A study led by Roswell Park Comprehensive Cancer Center provides new insight into the complex interactions of the "tumor-immune-gut axis," and its role in influencing immunotherapy responses in patients with recurrent ovarian ...
Dec 13, 2024
0
50
A firm handshake between proteins on immune cells is important for the body's ability to fight infection. Meanwhile, a weak grip helps explain the poor immune deficiencies caused by a rare genetic disorder.
Dec 10, 2024
0
15
Researchers at Uppsala University and KTH Royal Institute of Technology have developed a new form of precision medicine, an antibody, with the potential to treat several types of cancer. Researchers have managed to combine ...
Nov 11, 2024
0
31
Research from Radboud university medical center reveals that T cells from the adaptive immune system can manipulate the memory of innate immune cells. Previously, it was believed that the memory of innate immune cells operated ...
Aug 22, 2024
0
49
Endothelial-mesenchymal transition (EndoMT, also termed as EndMT), a biological process resulting in the formation of mesenchymal (or lineage-committed) phenotypes from endothelial cells (lining blood vessels), plays a crucial ...
Feb 7, 2024
0
25
Preeclampsia and other hypertensive disorders of pregnancy—which are characterized by high blood pressure with or without organ dysfunction during the second half of pregnancy—carry considerable short- and long-term risks ...
Jan 3, 2024
0
56
Medical investigators are theorizing that a combination of two treatments that activate myeloid cells may effectively treat a recalcitrant form of pancreatic cancer that thwarts conventional immunotherapy.
